6174-78-3

Upstream product

• 23287-26-5 3-methylsalicylic acid methyl ester 
• 83-40-9 3-methylsalicylic acid 

Downstream Products

• 40912-75-2 2-hydroxy-5-iodo-3-methylbenzoic acid methyl ester 
• 119754-19-7 2-Hydroxy-3-methyl-5-trimethylsilanylethynyl-benzoic acid methyl ester 
• 119754-23-3 methyl 5-ethynyl-2-hydroxy-3-methylbenzoate 

Relevant academic research and scientific papers

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Synthesis of Some Substituted Dimethyl and Diethyl 4-(Phenylethynyl)-2,6-pyridinedicarboxylates

Substituted dimethyl and diethyl 4-(phenylethynyl)-2,6-pyridinedicarboxylates were prepared by coupling reactions between dialkyl 4-halo-2,6-pyridinedicarboxylates and terminal arylacetylenes in the presence of an organopalladium catalyst and copper(I) iodide in a suitable solvent system.The terminal acetylenes needed in this work were synthesized from the corresponding aryl halides using either (trimethylsilyl)acetylene or 2-methyl-3-butyn-2-ol followed by deprotection of the triple bond, depending on the nature of the compound in question.